AMG820   Click here for help

GtoPdb Ligand ID: 9106

Immunopharmacology Ligand
Compound class: Antibody
Comment: AMG820 is a monoclonal antibody targeting the receptor tyrosine kinase, CSF1R (Fms). It is claimed in patent WO2009026303 [1].
Click here for help
No information available.
Summary of Clinical Use Click here for help
A Phase 1/II clinical trial evaluating an AMG820 and pembrolizumab (approved anti-PD-1 antibody) is underway- see NCT02713529.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Anti-CSF1R antibodies prevent binding of the receptor's endogenous ligand CSF1 (or M-CSF). This action reduces monocyte infiltration into tumours and inhibits the acumulation of tumour-associated macrophages (TAMs).
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02713529 Safety and Efficacy Study of AMG 820 and Pembrolizumab Combination in Select Advanced Solid Tumor Cancer Phase 1/Phase 2 Interventional Amgen